Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for AbbVie in a report released on Tuesday, ...

AbbVie Inc. closed 18.39% short of its 52-week high of $207.32, which the company achieved on October 31st.

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $172.61 which represents a slight increase of $1.05 or 0.61% from the prior close of $171.56. The stock opened at $172.16 and touched a ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Berenberg Bank analyst Richard Hatch maintained a Hold rating on AbbVie (ABBV – Research Report) yesterday and set a price target of $165.00.

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $171.56 which represents a decrease of $-2.14 or -1.23% from the prior close of $173.7. The stock opened at $172.88 and touched a ...

Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst S. Ganoria now ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...